Castration-resistant prostate cancer: systemic therapy in 2012 - Wikidata - wikimedia - TriplyDB

Castration-resistant prostate cancer: systemic therapy in 2012

Castration-resistant prostate cancer: systemic therapy in 2012

http://www.wikidata.org/entity/Q35865011

about

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Epigenetic modulators as therapeutic targets in prostate cancer Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells.Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.The hurdle of antiandrogen drug resistance: drug design strategies.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Role of PARP-1 in prostate cancer.Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer.[Pathophysiology and therapy of castration-resistant prostate cancer].Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.

P2860

Q26825053-63E1360E-A05E-442B-AC6E-7819821DF5F1 Q28071912-EB1062FA-58B0-44E6-9D8E-13B085C44789 Q36077939-768D2D74-AA81-47B2-8CA8-35B3BBE9221E Q36228550-A146A134-6DFC-4737-95B5-AB5331A5C04B Q38112122-5A349EC7-17E0-4AA4-B121-D46F110F6E59 Q38160927-1AB0ABB8-715F-4540-9331-96921B80BC3A Q38203779-89392C49-02E7-4C3F-BF0D-077381F0DE54 Q38526322-FD2D9A7C-2A90-4E77-ACEC-840EA78BFFC5 Q38844346-E8191658-AA53-4B91-8941-62EE8CB0D6B8 Q39596976-D384A089-AFC5-4C35-8C07-6496B159832D Q43220277-CFBD9A17-BE7B-4107-8B48-B0FC8451B227 Q45021228-07B41DB7-0C19-408F-B2CA-574DB62192C5 Q47361686-F93BEAED-1E63-460F-94B9-8C076A2793FE Q50856213-01C5430B-E270-4F8A-A24D-BBE473FE320E

P2860

Castration-resistant prostate cancer: systemic therapy in 2012

http://www.wikidata.org/entity/Q35865011

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Castration-resistant prostate cancer: systemic therapy in 2012

@ast

Castration-resistant prostate cancer: systemic therapy in 2012

@en

type

label

Castration-resistant prostate cancer: systemic therapy in 2012

@ast

Castration-resistant prostate cancer: systemic therapy in 2012

@en

prefLabel

Castration-resistant prostate cancer: systemic therapy in 2012

@ast

Castration-resistant prostate cancer: systemic therapy in 2012

@en

P1433

Q35865011-65EF125A-D445-4D88-B596-B4973E577603

P1476

Q35865011-22247EDC-3A44-4264-99F8-4C2D5EEC9141

P2093

Q35865011-1997ACDD-5741-4AAD-BBDA-41300965220E

Q35865011-C0F6BE7A-338B-4AB7-B9D0-152375F40354

P275

Q35865011-692D6FDF-B521-4C9F-8AFA-E81BB38813C8

P2860

Q35865011-01BD8891-2B0B-4099-B2B0-2ED84996767C

Q35865011-0322C493-40D6-4933-A2BD-589DCCB17534

Q35865011-046497EC-DCA9-44CD-BEDE-675672269E8C

Q35865011-0A395234-7EA5-4F4B-B962-8AA580939E49

Q35865011-0E79BFE3-ACA7-461D-B357-35FD9B16B052

Q35865011-1256E9A5-9348-42E6-BFDB-DAF6B6B92681

Q35865011-196D4200-91E0-4E5E-90DA-E9A9F6A639CB

Q35865011-1AEFD4F6-2C7B-4188-AA27-512CBA3F4CE3

Q35865011-1B1E6A5B-F7AF-4445-B5A3-57FC4F714B84

Q35865011-1C46037B-7C02-4B30-A230-1C82BB22E937

P304

Q35865011-177FDCFB-BF11-4468-AEBB-3830459EC23D

P31

Q35865011-02DC9BAD-1071-4F6A-BDF4-65E87FAFF592

P356

Q35865011-61187932-85EF-451D-8EC1-512095F3585D

P433

Q35865011-2F6567C0-E09E-4985-A360-94333B846679

P478

Q35865011-10BA521E-82AB-4738-B396-3D8C40EBCEB0

P50

Q35865011-D341EA9E-A4F1-4D87-A3B4-13E5655B30AC

P5008

Q35865011-267618FD-86F0-4405-A2E7-7645E5878808

P577

Q35865011-9EBDBBFD-2BF9-4B2D-985A-3BABFD52C749

P5875

Q35865011-9DE092CC-09F0-4AFC-95E7-02BEBE6D34C6

P698

Q35865011-7D6F2D3F-D585-4979-851F-9B79C98D3DE5

P921

Q35865011-76517C0F-DCD5-4D8A-BEEE-04FCD920B016

Q35865011-EFED3CE8-259B-476A-AE21-243008205A85

P932

Q35865011-74B911A2-8268-4FC5-84BB-55DC1F4F8DE7

P356

P1433

P1476

Castration-resistant prostate cancer: systemic therapy in 2012

@en

P2093

Daniel Herchenhorn

http://www.w3.org/2001/XMLSchema#string

Fernando C Maluf

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

P304

389-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6061/CLINICS/2012(04)13

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224811288

http://www.w3.org/2001/XMLSchema#string

P698

22522765

http://www.w3.org/2001/XMLSchema#string

P921

hormone antagonist

prostate cancer

P932

3317249

http://www.w3.org/2001/XMLSchema#string